Abstract: 【Abstract】 Objective To evaluate the short-term clinical efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis. Methods Thirty-six patients with moderate to severe psoriasis, who visited Department of Dermatology, Henan Provincial People′s Hospital from June 2019 to November 2019, received subcutaneous injection of secukinumab at a dose of 300 mg once a week for 5 weeks, followed by once every 4 weeks. Psoriasis area and severity index（PASI）was recorded at weeks 4, 8 and 12, and adverse drug reactions were observed during the treatment. Results All the 36 patients received the treatment for at least 12 weeks. At week 4, 8 patients achieved PASI75, including 3 achieving PASI90 and 1 achieving PASI100; at week 8, 26 achieved PASI75, of which 16 achieved PASI90 and 4 achieved PASI100; at week 12, 32 achieved PASI75, of which 26 achieved PASI90 and 8 achieved PASI100. No patients had serious adverse drug reactions, such as severe infections or malignancies. One patient developed abdominal pain and distension after subcutaneous injection in the abdomen, and the symptoms disappeared after 3 days; 1 patient developed tonsillitis followed by eczema-like lesions on the original psoriaitc lesions; suppurative lymphadenitis occurred in the neck of another patient. Conclusion Secukinumab is markedly effective in the treatment of moderate to severe plaque psoriasis with few adverse effects, and is a new treatment option for patients with moderate to severe plaque psoriasis.

Key words: Psoriasis, Biological agents, Treatment outcome, Toxic actions, Secukinumab